Is gosatuzumab an ADC drug?

Sacituzumab govitecan is a ADC drug, that is, Antibody-Drug Conjugate. ADC drugs are highly targeted therapies that consist of three main components: monoclonal antibodies, connectors, and drug payloads. Gosatuzumab is such an ADC drug.

Monoclonal antibodies are a key component of ADC drugs. It achieves targeted therapy by selectively binding to specific antigens overexpressed on the surface of tumor cells. In gosatuzumab, the monoclonal antibody works by binding to Trop-2 receptors on the surface of tumor cells.

Linkers are molecules that connect monoclonal antibodies to drug payloads. It has two key functions: first, stability. The connector can maintain the connection between the drug load and the monoclonal antibody to ensure that the drug is not easily released before entering the tumor cells; second, it can be recognized and cleaved by enzymes. When the ADC enters the tumor cells, the connector can be recognized and cleaved by the enzymes, thereby releasing the drug load.

The drug load is the "drug moiety" between the connector and the monoclonal antibody, which can be a chemotherapeutic drug, a cytotoxic drug or other therapeutic substance. In gosatuzumab, the drug load is a powerful chemotherapy drug called SN-38, which is an active metabolite of irinotecan.

In short,ADC drugs use monoclonal antibodies to deliver drugs to tumor cells and release drugs within the cells, thereby achieving the inhibitory effect on tumor cells. Gosatuzumab is an ADC drug that treats certain types of cancer by targeting Trop-2 receptors, providing patients with a new treatment option. However, the use of ADC drugs needs to be done under the guidance of a doctor to ensure safety and effectiveness.